APOB and cardiovascular disorder: They exert their effect by competitively inhibiting HMG-CR (see Figure 1), leading to reductions in serum total cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein-B (Apo-B), and triglycerides, thereby aiding in the prevention of cardiovascular disease (CVD) [133].